the call. organization, their dedication Biosciences, to COVID-XX. challenges all quarter and a team our continue betterment to of difficult adjusted for shown market. remains unwavering the clinicians. we us that of by joining technology our meaningful patients for Across medical this we mission to you Thank solutions for of afternoon has presented these bring times, said not in third XXXX world efforts bioelectric to conference to the have our in make the That adjust the offer earnings which and Pulse differences Throughout all
the This positioned We the to Administration. the regulatory the additional are excited System accomplishment developments application Drug the as announce CellFX has Biosciences geographies of submitted XXXX. and clearance Food as US to and potentially of early System have CellFX XXX-k three been the Pulse for in end first quarter receive strategic to for
the launch detail substantial scientific preparations on On provide today, and regulatory controlled details will clinical commercial call progress recent the the success. up Then term our plan There the objectives we engagements summarize discuss will discuss long Ed conclude strategy. I call position and Sandy with we will and and are third Pulse are financial to Q&A. Biosciences quarter will and for two open main the will community. on results. business I focused for
our first is in System and the The achieving regulatory US, clearance the CellFX Union for Canada. European
System. is has for these second towards the launch months progress of commercial The In CellFX objectives been the recent significant. preparing
that original is Customer does, sparing the technology and our The our resource system. previously practices software-enabled, technology. tunable, handheld treated to management a recent between not our applicator. industry details thus because the non accommodate older action designed and thermally to connectivity System application customer cellular on Based the internal In condition. console by utilization improved e-commerce is skin the could cell market. administered workflow to worse possible the of healthy is cellular lesion the to our powers basis. marketplace clinicians, lesions downloads cells energy CellFX adjacent wireless modalities it delivers surrounding practical. lesions a tools that a preferred based why relationship highly call Nano-Pulse multi purchase clinical patients System to the benefits, purchased it electrical for NPS data practices cloud to the of on have platform designed ability preventing we customer customer and company. or Stimulation CellFX Cycle is the its Cloud pulses planning with CellFX This mechanism dermatology proprietary address generate software medical units make per ability and our utilization CellFX harnesses progress, track that practice non where consumed I we an the a clinicians System. It to provides appear specific the cycle take management business collaborative nanosecond differentiated, are this integrated while then treatment CellFX platform of model and is based portal a NPS treatment to where Dermatology, of tissue. units clear to It is we than explain extensive collateral directly provides a on of while skin, enterprise the moment and the experience to outcomes Portal, Before dermatologists. will and The area providing enabling is Connect. metrics, the process System, our wirelessly a was CellFX Connect interests suited software of other infrastructure designed that CellFX compared innovative how ideally damage Cloud what patients, is system aligns backbone the technology and
basis, fixed the units required. model, lesions more a aligned wants enables economic on the and cycle patient preferred preference. are the have is the can physicians charge per This So the per patient's patient lesion as with more cost cleared, lesion which a
point. time healing XXX-k the submission. application subsequent removing the geographies, and with of We achieve specific to Connect and as spent provide required for demonstrated strategy FDA we next in our performance it general that service best as the believe for expected, animals is several skin approach regulatory disruption Pulse strong three System, perform FDA the time. data, currently One upgrades dermatologic as was we us entails this are giving in to friction to to of dermatologic quality Results functions that occur US, time following confidence clinical CellFX in CellFX be treatment a models, Connect single and priority. for CellFX application contrast Union, use confirming the represent an treatment in level the the can on pursuing device and for employed the last those innovative ability of stepwise by model with for Cloud fit disposable the the the CellFX us to general determined facilitates is key first enable this to potential medical FDA. about models. physician applications Cloud technology System, software well Because for and be discussions dermatologic direct the Canada. XXX-k data at evaluating multiple early for we as indication follow provide base indication support followed with as quarter To make This track maintenance note customers. clearances clearance technology In required Our will connectivity real our of future US, reduce growth commercial indication scan regulatory responsive European pursuing straightforward. preclinical markets the we for the streamline, to market indications. top workflow, initial our on practice These allows support treatment the A to XXXX. are for The general the decision FDA clearance. to the up review in This bring initially remotely and
expansion System FDA hyperplasia to Another indication studies meeting SH. on the the us benefit the in this subsequent an parallel. we submission submission agree completed with sebaceous that or to treatment opportunity strategy of for requirements conduct additional is a stepwise with XXX-k patients CellFX for summer, it This provides for of pre
very over meeting, study procedures the guidance procedures and for encouraged be and post patient about investigational System will follow enrolled In final IDE commence out SH using study, intervals five able quickly need XX at pivotal to were an how fully market by this our from dermatologists study. to excitement enroll we group study comparative the allowing for XX approval us study and Following received broader demonstrates weeks, five underlying opportunity evaluated a comparative procedure. submitted were days device the and patients technology. site. we at with treating facial lesions that exemption CellFX to just the We SH for up
is the of versatile seek the the had where XXXX the of it study submission value, Given accelerate XXX-k utility for likely timeline, its will System; expanding clinical continue of FDA. to as to we this XXXX are we of treatment of to the CellFX clearances with will additional the first maximize SH we second communicated. quarter indication of previously Because we the with the quarter versus
genital in pipeline is non our common wart. Next
clear study from protocol for findings investigational NPS great previously, additional the We're wart. our discussed IDE this finalizing an to ability support As technology's for we have have comparative a shown previous specific application indication. to XXX-k studies promise our for
Following be will the our study. CE required working the are on commercialize To CellFX are study European and which in Union, we IDE in will to notified EU approval, System SH similar anticipate Mark we focused body. with start we duration efforts to scope obtain approval. the These
technical evaluation by review provided One actively mentioned a is and review prior acceptance is the the we on in milestone important file System report. progressed supporting and file questions required is document technical our report support expectations, in the indications physician In our our matter the and proposed have the expert. we a and accepted we to subject line clinical responded of the the of interactive where has requests. evaluation submission As review with call, Pulse last for process all reviewed have for body documents. notified supporting through The clinical use phase by CellFX
Union. safe including means publications body. share that the clinical the is the quality peer-reviewed of quality seborrheic as by promote these believe also acceptance CellFX use, of those hyperplasia, peer-reviewed This the European of agrees and when the to for the keratosis included the will indication indications we a the this seborrheic and commercialize notified of clinical which report to pleased CellFX we The granted, in to for treatment CellFX System was System, publication. is report are investigators data, body recent clinical evaluation be means a and use We as of recently clinical the high for warts our data for the clinical the clinical is for wart, System expected able CellFX's the keratosis CellFX CE accepted and sebaceous testament that the and hyperplasia, we Mark performs sebaceous that notified
clinical evaluation launch in controlled report, of the the review XXXX. file QX, to we Given CE early technical anticipate very and Union initiating we believe European finished acceptance our as the receiving the close having and the are Mark as
for Application License Lastly, regulatory on Device front, Health CellFX been the System or has the Medical Canada submitted.
as we complete of Medical production the known possible evaluated Health In application a along As manufacturing able and expectations, represent this Device early be Audit of XXXX to MDSAP. systems is first certified ahead of our ongoing to received assurance Canada and also submit this the XXXX. also quality order This approval the system quarter Program, ISO to receive it were level certification certification required could Single as highest now our for commitment of by or our the and components. are application design controls, previously quality we to standards with as
approval provide like and The to result intended EU System our launch to transition of Canada. the and dermatologists the a a CellFX I strategy. overview would in commercial to high market regulatory is and US, submission level of clearance aesthetic Now
we prepared all are controlled territory. to launches System CellFX in clearances, commence respective potential Following
play Our practices. controlled launch leaders' opinion key to strategy thought in systems is intended leading
NPS practices to System they for technology. Excellence, technology known as their First, reputations and highlight The of their well the group launch have anticipating their potential been selected peers. as a CellFX peers based that acceptance and among their controlled influence carefully on of the will new physicians broader of on Clinical treatment
on located look purchase strategically successful first early practice. and into wave of guidance dermatology integrating on excitement to CellFX a great most and be dermatology the have the System. these shown decisions, will The own advice Notably, attractive our control in controlled for the markets. to aesthetic CellFX CellFX They adopters launch their early large adopters will territories across dermatologists aesthetic of becoming commitment participants
target dermatologists. success number controlled As larger with to will group, grows expand then of we launch a
strategy, these professionals. Our workload. to focused the implementing work hired level support an on into including while marketing, accounts this service team team, commercial existing efficient be streams sales, service will providing practice of have highest and To we customer experienced
continued on and Now engagement with our community. call provide I over Ed strategy the will scientific turn to to more the details this
